BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “neutral” rating restated by equities researchers at Seaport Global Securities in a research report issued on Thursday.
Other research analysts also recently issued research reports about the company. BidaskClub upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 4th. Zacks Investment Research upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research note on Tuesday, May 1st. Finally, ValuEngine upgraded BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $8.36.
BioCryst Pharmaceuticals opened at $5.73 on Thursday, according to Marketbeat.com. BioCryst Pharmaceuticals has a one year low of $3.95 and a one year high of $6.67. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.38 and a quick ratio of 1.38.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.10). BioCryst Pharmaceuticals had a negative net margin of 392.09% and a negative return on equity of 114.36%. The business had revenue of $3.98 million during the quarter, compared to analysts’ expectations of $10.20 million. research analysts anticipate that BioCryst Pharmaceuticals will post -0.89 earnings per share for the current year.
In related news, CMO William P. Sheridan sold 42,112 shares of the firm’s stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $6.30, for a total transaction of $265,305.60. Following the transaction, the chief marketing officer now owns 63,170 shares in the company, valued at approximately $397,971. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.21% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in BioCryst Pharmaceuticals by 15.0% during the 4th quarter. BlackRock Inc. now owns 7,614,280 shares of the biotechnology company’s stock worth $37,386,000 after acquiring an additional 993,100 shares during the period. Citadel Advisors LLC lifted its position in BioCryst Pharmaceuticals by 4,343.1% during the 1st quarter. Citadel Advisors LLC now owns 462,079 shares of the biotechnology company’s stock worth $2,204,000 after acquiring an additional 451,679 shares during the period. Rock Springs Capital Management LP lifted its position in BioCryst Pharmaceuticals by 80.6% during the 4th quarter. Rock Springs Capital Management LP now owns 812,500 shares of the biotechnology company’s stock worth $3,989,000 after acquiring an additional 362,500 shares during the period. Deutsche Bank AG lifted its position in BioCryst Pharmaceuticals by 106.1% during the 4th quarter. Deutsche Bank AG now owns 524,666 shares of the biotechnology company’s stock worth $2,573,000 after acquiring an additional 270,147 shares during the period. Finally, UBS Group AG lifted its position in BioCryst Pharmaceuticals by 190.7% during the 1st quarter. UBS Group AG now owns 291,379 shares of the biotechnology company’s stock worth $1,390,000 after acquiring an additional 191,157 shares during the period. Hedge funds and other institutional investors own 89.91% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.